8-K 1 rgbp081319form8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 13, 2019

 

REGEN BIOPHARMA, INC.

(Exact name of small business issuer as specified in its charter)

 

Nevada 45-5192997
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)

 

Commission File No. 333-191725

 

4700 Spring Street, St 304, La Mesa, California 91942

(Address of Principal Executive Offices)

 

(619) 702 1404

(Issuer’s telephone number)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 1 

 

 

Item 8.01 Other Events

On August 13, 2019 Dr. Harry Lander requested that 5,000,000 common shares of KCL Therapeutics, Inc. (“KCL”) owned by Dr. Lander be cancelled

The abovementioned common shares were issued to Dr. Lander pursuant to a consulting agreement entered into on January 23, 2019 by and between Dr. Lander and KCL.

Upon effective cancellation of the 5,000,000 common shares owned by Dr. Lander, Regen Biopharma, Inc. will own 100% of KCL.

 2 

 

 

SIGNATURE 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  REGEN BIOPHARMA, INC.
   
Dated: August 13, 2019 By: /s/ David Koos
  David Koos
  Chief Executive Officer

 3